623 related articles for article (PubMed ID: 20184589)
1. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
[TBL] [Abstract][Full Text] [Related]
2. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
Califf RM; Boolell M; Haffner SM; Bethel M; McMurray J; Duggal A; Holman RR;
Am Heart J; 2008 Oct; 156(4):623-32. PubMed ID: 18946890
[TBL] [Abstract][Full Text] [Related]
3. Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Latini R; Staszewsky L; Sun JL; Bethel MA; Disertori M; Haffner SM; Holman RR; Chang F; Giles TD; Maggioni AP; Rutten GE; Standl E; Thomas L; Tognoni G; Califf RM; McMurray JJ
Am Heart J; 2013 Nov; 166(5):935-40.e1. PubMed ID: 24176451
[TBL] [Abstract][Full Text] [Related]
4. Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.
Wong YW; Thomas L; Sun JL; McMurray JJ; Krum H; Hernandez AF; Rutten GE; Leiter LA; Standl E; Haffner SM; Mazzone T; Martinez FA; Tognoni G; Giles T; Califf RM
Circ Heart Fail; 2013 Mar; 6(2):203-10. PubMed ID: 23388113
[TBL] [Abstract][Full Text] [Related]
5. [NAVIGATOR: A trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide].
Scheen AJ
Rev Med Liege; 2010 Apr; 65(4):217-23. PubMed ID: 20499825
[TBL] [Abstract][Full Text] [Related]
6. Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Preiss D; Giles TD; Thomas LE; Sun JL; Haffner SM; Holman RR; Standl E; Mazzone T; Rutten GE; Tognoni G; Chiang FT; McMurray JJ; Califf RM
Stroke; 2013 Sep; 44(9):2590-3. PubMed ID: 23899915
[TBL] [Abstract][Full Text] [Related]
7. Role of renin-angiotensin system blockade in patients with diabetes mellitus.
Braga MF; Leiter LA
Am J Cardiol; 2009 Sep; 104(6):835-9. PubMed ID: 19733720
[TBL] [Abstract][Full Text] [Related]
8. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
[TBL] [Abstract][Full Text] [Related]
9. International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
Harumi Higuchi Dos Santos M; Sharma A; Sun JL; Pieper K; McMurray JJ; Holman RR; Lopes RD
J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28087508
[TBL] [Abstract][Full Text] [Related]
10. Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
Shen L; Shah BR; Reyes EM; Thomas L; Wojdyla D; Diem P; Leiter LA; Charbonnel B; Mareev V; Horton ES; Haffner SM; Soska V; Holman R; Bethel MA; Schaper F; Sun JL; McMurray JJ; Califf RM; Krum H
BMJ; 2013 Dec; 347():f6745. PubMed ID: 24322398
[TBL] [Abstract][Full Text] [Related]
11. Effect of valsartan on the incidence of diabetes and cardiovascular events.
; McMurray JJ; Holman RR; Haffner SM; Bethel MA; Holzhauer B; Hua TA; Belenkov Y; Boolell M; Buse JB; Buckley BM; Chacra AR; Chiang FT; Charbonnel B; Chow CC; Davies MJ; Deedwania P; Diem P; Einhorn D; Fonseca V; Fulcher GR; Gaciong Z; Gaztambide S; Giles T; Horton E; Ilkova H; Jenssen T; Kahn SE; Krum H; Laakso M; Leiter LA; Levitt NS; Mareev V; Martinez F; Masson C; Mazzone T; Meaney E; Nesto R; Pan C; Prager R; Raptis SA; Rutten GE; Sandstroem H; Schaper F; Scheen A; Schmitz O; Sinay I; Soska V; Stender S; Tamás G; Tognoni G; Tuomilehto J; Villamil AS; Vozár J; Califf RM
N Engl J Med; 2010 Apr; 362(16):1477-90. PubMed ID: 20228403
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin receptor blockers: Cardiovascular protection in the metabolic syndrome.
Deedwania PC; Schmieder R
J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S12-8. PubMed ID: 16986230
[TBL] [Abstract][Full Text] [Related]
13. Navigating the choices for diabetes prevention.
Nathan DM
N Engl J Med; 2010 Apr; 362(16):1533-5. PubMed ID: 20228400
[No Abstract] [Full Text] [Related]
14. Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial.
Aksnes TA; Kjeldsen SE; Rostrup M; Störset O; Hua TA; Julius S
J Hum Hypertens; 2008 Aug; 22(8):520-7. PubMed ID: 18509347
[TBL] [Abstract][Full Text] [Related]
15. People with impaired glucose tolerance and impaired fasting glucose are similarly susceptible to cardiovascular disease: a study in first-degree relatives of type 2 diabetic patients.
Amini M; Horri N; Zare M; Haghighi S; Hosseini SM; Aminorroaya A; Hovsepian S
Ann Nutr Metab; 2010; 56(4):267-72. PubMed ID: 20413967
[TBL] [Abstract][Full Text] [Related]
16. Effect of nateglinide on the incidence of diabetes and cardiovascular events.
; Holman RR; Haffner SM; McMurray JJ; Bethel MA; Holzhauer B; Hua TA; Belenkov Y; Boolell M; Buse JB; Buckley BM; Chacra AR; Chiang FT; Charbonnel B; Chow CC; Davies MJ; Deedwania P; Diem P; Einhorn D; Fonseca V; Fulcher GR; Gaciong Z; Gaztambide S; Giles T; Horton E; Ilkova H; Jenssen T; Kahn SE; Krum H; Laakso M; Leiter LA; Levitt NS; Mareev V; Martinez F; Masson C; Mazzone T; Meaney E; Nesto R; Pan C; Prager R; Raptis SA; Rutten GE; Sandstroem H; Schaper F; Scheen A; Schmitz O; Sinay I; Soska V; Stender S; Tamás G; Tognoni G; Tuomilehto J; Villamil AS; Vozár J; Califf RM
N Engl J Med; 2010 Apr; 362(16):1463-76. PubMed ID: 20228402
[TBL] [Abstract][Full Text] [Related]
17. Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
Chatterjee R; Thomas L; Svetkey L; Brancati FL; Califf RM; Edelman D
Am J Hypertens; 2013 Jun; 26(6):723-6. PubMed ID: 23417031
[TBL] [Abstract][Full Text] [Related]
18. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score.
Tuomilehto J; Lindström J; Hellmich M; Lehmacher W; Westermeier T; Evers T; Brückner A; Peltonen M; Qiao Q; Chiasson JL
Diabetes Res Clin Pract; 2010 Feb; 87(2):267-74. PubMed ID: 20022651
[TBL] [Abstract][Full Text] [Related]
20. Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome--the Chennai Urban Rural Epidemiology Study.
Gokulakrishnan K; Deepa R; Mohan V; Gross MD
Metabolism; 2006 Feb; 55(2):237-42. PubMed ID: 16423632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
